Large cell lung cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:10 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Large cell lung cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC). The study is exploring a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy is designed to target specific mutations found in cancer cells. The study will also look at how ATL001 works when used alone and in combination with another medication called pembrolizumab, which is already used in cancer treatment.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

]]>